Corbus Pharmaceuticals (CRBP)
(Real Time Quote from BATS)
$51.30 USD
+0.22 (0.43%)
Updated Jul 10, 2024 09:32 AM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CRBP 51.30 +0.22(0.43%)
Will CRBP be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CRBP based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRBP
Here's What Could Help Corbus Pharmaceuticals (CRBP) Maintain Its Recent Price Strength
What Makes Corbus Pharmaceuticals (CRBP) a Good Fit for 'Trend Investing'
CRBP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Alpine Immune Sciences (ALPN) Stock Outpacing Its Medical Peers This Year?
Is Corbus Pharmaceuticals (CRBP) Stock Outpacing Its Medical Peers This Year?
Are Medical Stocks Lagging HealthEquity (HQY) This Year?
Other News for CRBP
Bearish Friday For Marijuana Stocks - Global Compliance, 1933 Industries Among Top Gainers
Buy Rating Justified by Corbus Pharmaceuticals’ Promising Drug Pipeline and Market Potential
Corbus initiated with Buy on potential in weight loss at B. Riley
Corbus Pharmaceuticals initiated with bullish view at B. Riley
Corbus Pharmaceuticals management to meet with Oppenheimer